EGFR and non-small cell lung carcinoma: This study hypothesized that combination of CHM and EGFR-TKIs may prolong PFS, increase tumor response, improve performance status, and reduce toxicities in advanced NSCLC patients harboring EGFR sensitizing mutation, compared with use of EGFR-TKIs alone.